These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10512491)

  • 21. Lessons from the TOPCAT trial.
    McMurray JJ; O'Connor C
    N Engl J Med; 2014 Apr; 370(15):1453-4. PubMed ID: 24716685
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
    Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
    J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
    [No Abstract]   [Full Text] [Related]  

  • 24. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
    de Denus S; O'Meara E; Desai AS; Claggett B; Lewis EF; Leclair G; Jutras M; Lavoie J; Solomon SD; Pitt B; Pfeffer MA; Rouleau JL
    N Engl J Med; 2017 Apr; 376(17):1690-1692. PubMed ID: 28445660
    [No Abstract]   [Full Text] [Related]  

  • 25. Aldosterone antagonism in heart failure.
    Richards AM; Nicholls MG
    Lancet; 1999 Sep; 354(9181):789-90. PubMed ID: 10485716
    [No Abstract]   [Full Text] [Related]  

  • 26. [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
    Takata Y; Asano K; Yamashina A
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():336-41. PubMed ID: 15813091
    [No Abstract]   [Full Text] [Related]  

  • 27. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
    Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
    Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The TOPCAT study].
    Boccanelli A; Pulignano G
    G Ital Cardiol (Rome); 2014 Oct; 15(10):521-6. PubMed ID: 25424015
    [No Abstract]   [Full Text] [Related]  

  • 29. [The place of aldosterone receptor blockers in the treatment of chronic heart failure].
    Kardiologiia; 2005; 45(10):76-81. PubMed ID: 16234778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplerenone in mild heart failure.
    Tomaschitz A; Pilz S; März W
    N Engl J Med; 2011 Apr; 364(14):1371; author reply 1372. PubMed ID: 21470018
    [No Abstract]   [Full Text] [Related]  

  • 32. Eplerenone in mild heart failure.
    Gus M; Fuchs FD
    N Engl J Med; 2011 Apr; 364(14):1370-1; author reply 1372. PubMed ID: 21470019
    [No Abstract]   [Full Text] [Related]  

  • 33. Patients' interest overlooked.
    Prescrire Int; 2013 Jun; 22(139):148. PubMed ID: 23866348
    [No Abstract]   [Full Text] [Related]  

  • 34. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 35. [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
    Watanabe J
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():543-6. PubMed ID: 17508588
    [No Abstract]   [Full Text] [Related]  

  • 36. Aldosterone antagonists--last man standing?
    Armstrong PW
    N Engl J Med; 2011 Jan; 364(1):79-80. PubMed ID: 21073364
    [No Abstract]   [Full Text] [Related]  

  • 37. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
    Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
    JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of spironolactone in patients with severe heart failure.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir J Med Sci; 2003; 172(2):70-2. PubMed ID: 12930056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CHARM programme.
    Gama MG; Rocha G
    Lancet; 2003 Nov; 362(9396):1676; author reply 1678-9. PubMed ID: 14630454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.